New and Emerging Therapies for Soft Tissue Sarcomas and GIST: Recent Clinical Data and Expert Recommendations
|
|
- Phebe Lloyd
- 5 years ago
- Views:
Transcription
1 New and Emerging Therapies for Soft Tissue Sarcomas and GIST: Recent Clinical Data and Expert Recommendations George D. Demetri, M.D. Director, Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Director, Ludwig Center at Harvard Professor of Medicine, Harvard Medical School Boston, Massachusetts 2018 Oncology Master Class
2 DISCLOSURES FOR GEORGE D. DEMETRI, MD Scientific consultant: Bayer, Pfizer, Novartis, Lilly, EMD-Serono, GlaxoSmithKline, Sanofi, Janssen, PharmaMar, ZioPharm, Daiichi-Sankyo, Polaris, Eisai, AdaptImmune, Ignyta, Mirati Consultant/SAB member with minor equity holding: G1 Therapeutics, Caris Life Sciences, Champions Biotechnology Independent Member of Board of Directors and Scientific Advisory Board Consultant with minor equity holding: Blueprint Medicines and Merrimack Pharmaceuticals Off Label/Investigational Discussion In accordance with Annenberg Center policy, faculty have been asked to disclose discussion of unlabeled or unapproved use(s) of drugs or devices during the course of their presentations. 2
3 Two Broad Clinical Groups of Sarcomas Soft Tissue Sarcomas (90%) Bone Sarcomas (10%)
4 Soft Tissue Sarcoma is not a single disease Unclassifiable GIST Leiomyo- Sarcomas Liposarcomas
5 Soft Tissue Sarcomas represent a very heterogeneous set of diseases Unclassifiable GIST Leiomyo- Sarcomas Liposarcomas Ducimetiere et al. PLoS ONE 6(8): e doi: /journal.pone
6 Gastrointestinal Stromal Tumor (GIST) Most common form of soft tissue sarcoma 1 Dominant Mutationally-Activated Receptor Tyrosine Kinase in each individual patient drives 90% of metastatic GIST Stomach 60% Eso / Duodenum 5% KIT (80%) 9 Exons PDGFRA (10%) Extracellular Domain Small intestine 30% TM Domain JM Domain Colon / rectum 5% 13 Kinase Domain-1 Malignant precursors of the GI pacemaker interstitial cells of Cajal Primary generally in stomach or small intestine Metastases in liver, abdomen, elsewhere Completely resistant to cytotoxic chemotherapy Barnett & Heinrich (2012) Am Soc Clin Oncol Educ Book; Nowain et al (2005) J Gastroen Heptol;20: Dematteo et al (2000) Ann Surg;231(1):51-8 Plumb et al (2013) Clin Radiol;68: Primary mutational hotpots KIT Exon 11 or 9 Kinase Domain-2 (activation loop) PDGFRα Exon 18 or 12 TKI Resistance mutations KIT Exons 13 and 17 PDGFRα Exon 18
7 Precision Cancer Medicine for GIST: Gene Mutations Matter SPECIFIC MUTATIONS impact patient outcomes GIST KIT mutation (80%) PDGFRA mutation (10% in met, 25% in gastric primary) SDH mutation or deficiency (either SDHA, SDHB, or SDHC) (approx. 10%) BRAF or NF1 mutations; TRK fusions (<2%) KIT exon 11 point mutations confer overall favorable prognosis KIT exon 9 mutations associated with worse prognosis PDGFRA mutation = good risk in primary GIST BUT worse outcomes in metastatic GIST Corless CL, et al. Nat Rev Cancer. 2011;11(12):
8 Long Term Overall Survival (OS) in Metastatic GIST Patients treated with imatinib as first-line tyrosine kinase inhibitor (TKI) ALL PATIENTS PATIENTS BY GIST PRIMARY KIT MUTATION From: Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results - Analysis of Phase 3 SWOG Intergroup Trial S0033 JAMA Oncol. Published online February 09, doi: /jamaoncol
9 Different PDGFRA mutations induce different clinical outcomes in metastatic GIST Progression-Free Survival Overall Survival Philippe A. Cassier et al. Clin Cancer Res 2012;18: by American Association for Cancer Research
10 Does adjuvant TKI therapy benefit patients with early stage, localized primary GIST? Which GIST patients need adjuvant therapy? (and which patients do not benefit)?
11 Quantifying the Risk of Recurrence for Primary Localized GIST (resected without prior imatinib) Tumor Parameters % RISK OF RELAPSE or METASTASIS Size Mitotic Count Stomach Duodenum Jejunum / Ileum Rectum 2 cm > 2, 5 cm per 50 > 5, 10 cm HPFs 4 24 } > 10 cm cm 0* * 50* 54 > 2, 5 cm > 5 per 50 > 5, 10 cm HPF 55 } 85 > 10 cm * Too few cases Adapted from Miettinen and Lasota. Sem Diag Pathol. 2006; 23(2): See also Joensuu H et al. Lancet Oncol 2012; 13: Adapted from Miettinen and Lasota. Sem Diag Pathol. 2006; 23(2): } 57 } 71
12 Improved Overall Survival with 3 yrs vs. 1 yr of Adjuvant Imatinib in GIST % % 92.0% 94.0% 81.7% 3 Years IM 1 Year IM 60 Hazard ratio (95% CI ) 20 P = No. at risk (n=397) Years 36 Months of imatinib Months of imatinib Joensuu H, et al
13 GIST genotype impacts whether adjuvant imatinib has any benefit following resection of primary localized GIST % Recurrence-Free and Alive NO benefit with adjuvant imatinib therapy for GIST with no mutations in KIT or PDGFRA ( Wild Type GIST) Imatinib Rx p= at 24 months Time in Months Placebo (n=32) Imatinib (n=32) Corless et al ASCO 2010
14 % Recurrence-Free and Alive GIST genotype impacts whether adjuvant imatinib has any benefit following resection of primary localized GIST NO benefit with adjuvant imatinib therapy for GIST with the PDGFRA Mutation Imatinib Rx Imatinib (n=15) Placebo (n=13) p= Also note the very good prognosis of patients with primary localized GIST harboring this mutation Time in Months Corless et al ASCO 2010
15 Understanding TKI Resistance in GIST to Overcome It: Differential resistance to current TKI Rx with KIT resistance mutations Predicted sensitivity profiles of imatinib, sunitinib, and regorafenib Resistant Sensitive PRIMARY MUTATIONS KIT Exon 9: 12% KIT Cell membrane SECONDARY MUTATIONS Exon 13 V654A Exon 14 T670I Imatinib DRUG SENSITIVITY Sunitinib Regorafenib Exon 11: 70% ATP-binding pocket Exon 17 D816E D820A/Y Activation loop Exon 18 N822K Adapted from Serrano-García C, et al. ASCO Abstract
16 New agents can be designed as potent, highly selective inhibitors of KIT and PDGFRα mutants resistant to imatinib and other TKIs Approved Standard of Care Drugs for GIST in 2018 Non-selective Type I inhibitors Avapritinib (BLU-285) imatinib sunitinib regorafenib crenolanib Kinome screening at 3 µm Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. ( Adapted from Evans E, et al. AACR
17 New agents can be designed as potent, highly selective inhibitors of KIT and PDGFRα mutants resistant to imatinib and other TKIs TKI resistance Mutants in Kinase Activation loop DOUBLE MUTANTS In both kinase JM domain and activation loop Compound Exon 18 PDGFRα IC 50 nm Exon 17 Exon 11/17 KIT KIT D816V V560G/D816V IC 50 nm IC 50 nm BLU imatinib sunitinib regorafenib midostaurin crenolanib New Agent inhibits mutant kinases Standard Drugs (Type II inhibitors) Are INACTIVE Non-selective Type I inhibitors Approved Standard of Care Drugs for GIST in 2018 Avapritinib (BLU-285) imatinib sunitinib regorafenib crenolanib midostaurin Kinome screening at 3 µm Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. ( Adapted from Evans E, et al. AACR
18 Antitumor activity of Avapritinib (BLU-285) in PDGFRA D842-mutant GIST Maximum reduction: sum of diameter change from baseline (%) of 31 (100%) patients with tumor shrinkage by central radiology review D V D842-H845V 20 PD Mutation status* SD PR -100 Numbers under bars indicate dose level CR * per archival tumor and ctdna Adapted from Heinrich, M., et al. CTOS 2017
19 DCC-2618, a novel pan-kit and PDGFRA Kinase Switch Control Inhibitor: Best Response in Advanced GIST patients per RECIST (n = 37) Somaiah N, et al. CTOS Annual Meeting 2017
20 How to Avoid or Overcome TKI Resistance in GIST Several trials designed to overcome resistance Combinations of drugs or other new agents PLX-9486 Crenolanib Immuno-Oncology Checkpoint inhibitors have been negative to date in GIST (but new combinations are being studied) Clinical trial participation is key to improving outcomes
21 Update on Managing Sarcomas other than GIST
22 Physicians (and patients) have lots of systemic therapy options for management of advanced Soft Tissue Sarcomas
23 Dose-Intense Combination Chemotherapy has marginal additional benefit over single-agent doxorubicin for unselected metastatic soft tissue sarcomas
24 Doxorubicin + ifosfamide Combination Chemotherapy vs. Doxorubicin alone for Metastatic Soft Tissue Sarcomas: EORTC Eligibility: High grade STS (2-3) Age No previous chemo for advanced/metastatic disease WHO PS < 2 Stratification: Age (<50 vs 50) PS (0 vs 1) Liver metastases (0 vs +) Histological grade (2 vs 3) Single-agent Doxorubicin (75 mg/m 2 bolus or as a 72 hour continous i.v. infusion) R New Treatment: Doxorubicin B 25 mg/m 2 d Ifosfamide 2.5 g/m 2 d PEG-Filgrastim 6 mg s.c. d5 Judson I, et al. ESMO 2012 and Lancet Oncol Mar 4.
25 Significantly Better Objective Response Rate for Combination Dox + Ifos Treatment Doxo (n=228) Doxo-Ifos (n=227) Total (n=455) n (%) n (%) n (%) Complete Response 1 (0.4) 4 (1.8) 5 (1.1) Partial Response 30 (13.2) 56 (24.7) 86 (18.9) Overall RESPONSE RATE ** No Change 105 (46.1) 114 (50.2) 219 (48.1) Progressive Disease 74 (32.5) 30 (13.2) 104 (22.9) Early Death - Progression 4 (1.8) 5 (2.2) 9 (2.0) Early Death Other cause 3 (1.3) 2 (0.9) 5 (1.1) Not evaluable 11 (4.8) 16 (7.0) 27 (5.9) ** Significant difference between the two arms: p < Judson I, et al. ESMO 2012 and Lancet Oncol Mar 4. 25
26 Progression-Free Survival: Statistically Different (p=0.003) Favoring Dox+Ifos Dox + Ifos Median PFS: 7.4 months (ORR 27%) Dox Median PFS 4.6 months (ORR 14%) (year) Judson I, et al. ESMO 2012 and Lancet Oncol Mar 4. 26
27 Overall survival: Dox+Ifos = Dox alone HR = 0.83 (95.5% CI ) Stratified logrank test, p = No difference statistically (years) O N Number of patients at risk : Treatment Doxo DxIf Judson I, et al. ESMO 2012 and Lancet Oncol Mar 4. 27
28 No Significant Improvement in Clinical Outcomes with Adjuvant Combination Chemotherapy (doxorubicin+ifos) vs. observation for Unselected Soft-Tissue Sarcoma Patients Following Resection Minor Benefit in Relapse-Free Survival only in first 3 years Woll PJ et al. Lancet Oncology, 2012 Oct;13(10):
29 Improving on chemotherapy alone with addition of Olaratumab, a Monoclonal Ab targeting PDGFRA Fully human monoclonal antibody of immunoglobin G class 1 (IgG1) that selectively binds PDGFRα 1 Blocks PDGF binding and PDGF-induced signalling 1 Demonstrated activity in both in vitro and in vivo cancer models known to be driven by a PDGF-PDGFRα autocrine loop 2 Demonstrated antitumor activity alone 1 or in combination with doxorubicin in human sarcoma xenograft models 1. Loizos N et al. Mol Cancer Ther. 2005;4: Gerber DE et al. Mol Cancer Ther. 2012;11:
30 Doxorubicin +/- Olaratumab Open-Label, Multicenter, Phase 1b/2 Trial Phase 2 Advanced STS Stratification: PDGFRα expression by IHC # Lines of prior treatment ECOG PS Histology (leiomyosarcoma, synovial sarcoma, other STS) R A N D O M I Z A T I O N Olaratumab 15 mg/kg d 1 and 8 + Dox 75 mg/m 2 d 1 x 8 cycles (21 d) a Doxorubicin alone 75 mg/m 2 d 1 x 8 cycles Olaratumab monotherapy until progression Olaratumab monotherapy after progression (optional) Primary endpoint: PFS (predefined statistical significance: 2-sided alpha = 0.2) Secondary endpoints: OS, ORR, PFS at 3 mo Biomarker: PDGFRα (IHC) and related ligands a During cycles 5-8, patients receiving Dox could receive dexrazoxane, at the investigator s discretion. Tap W et al. ASCO Abstract and Lancet 2016; 388:
31 Doxorubicin +/- Olaratumab Open-Label, Multicenter, Phase 1b/2 Trial PFS Median 6.6 vs 4.1 months (N.S.) OS Median 26.5 vs 14.7 months (p = ) U.S. FDA and European Medicines Agency Accelerated Approval and Conditional Approval in November 2016 Tap W et al. ASCO Abstract and Lancet 2016; 388:
32 Histology-Specific Management of Soft Tissue Sarcomas
33 Phase III Study Design in chemo-refractory STS PAZOPANIB vs. PLACEBO R A N D O M I Z E 2:1 Pazopanib (800 mg QD) n=246 Placebo (Matching dose 800 mg) n=123 Primary Endpoint PFS by Independent Review Secondary Endpoints Overall Survival Overall Response Rate Quality of Life Safety N= 369 Soft Tissue Sarcomas (Excluding LIPOSARCOMA and GIST) after chemo failure Stratification Factors: Performance status # of Prior lines of systemic therapy for advanced disease NO cross-over of patients on placebo to pazopanib A 33
34 Pazopanib Significantly Improves Progression-Free Survival but not Overall Survival in Metastatic Soft Tissue Sarcomas progressing after standard chemotherapy Van der Graaf W, et al. Lancet 2012: 379; A 34
35 Trabectedin is associated with better patient outcomes in leiomyosarcomas and liposarcomas than other subtypes of Soft Tissue Sarcomas: Expanded Access Trial Trabectedin, a marine-derived DNA minor groove binding drug Samuels BL et al. Annals of Oncology, Volume 24, Issue 6, 1 June 2013, Pages
36 Improved Disease Control (PFS) with Trabectedin vs. Dacarbazine in Leiomyosarcomas and Liposarcomas PFS events: 329 (63.5% of 518 patients) mpfs Trabectedin: 4.2 months mpfs Dacarbazine: 1.5 months HR (95% CI) = 0.55 (0.436,0.696) p< Unstratified analysis Demetri GD et al. J Clin Oncol Mar 10;34(8):786-93
37 PFS Improved for both Leios and Lipos with Trabectedin Demetri GD et al. J Clin Oncol Mar 10;34(8):786-93
38 Overall Survival (Final Analysis): Trabectedin vs. Dacarbazine Phase 3 Trial in Leiomyosarcomas and Liposarcomas OS events: 381 median OS Trabectedin: 13.7 months median OS Dacarbazine: 13.1 months HR (95% CI)=0.927 (0.748, 1.150) p= Patel S. et al. ESMO Vienna Sept 2015
39 Trabectedin: Histology-specific FDA approval October 2015 Trabectedin is FDA approved for leiomyosarcomas and liposarcomas after prior doxorubicin-based chemotherapy
40 Eribulin vs. Dacarbazine in Leiomyosarcomas and Liposarcomas: No Difference in PFS (Secondary Endpoint) for all patients Survival Probability Eribulin, a marine-derived microtubule-targeting Eribulin drug Eribulin Dacarbazine Median (months) Dacarbazine HR (95% CI) (0.710, 1.085) Stratified P- value Survival Time (months) Patients at Risk: Eribulin Dacarbazine Schöffski P et al. Lancet. 2016;387:
41 Eribulin vs. Dacarbazine in Leiomyosarcomas and Liposarcomas: Significantly better OS (primary endpoint) with eribulin Survival Probability Eribulin Dacarbazine Eribulin Dacarbazine Median (months) HR (95% CI) (0.618, 0.954) Stratified P-value Survival Time (months) Patients at Risk: Eribulin Dacarbazine Primary endpoint of OS was met, indicating a 2-month improvement in median OS with eribulin Schöffski P et al. Lancet. 2016;387:
42 NO IMPROVEMENT with Eribulin over Dacarbazine for Leiomyosarcomas in the Preplanned OS subgroup analysis Events/n Group/Subgroup Eribulin Dacarb Histology LIPOSARCOMA LEIOMYOSARCOMA 52/71 124/ /72 118/15 2 HR (95% CI) (0.346, 0.753) (0.714, 1.203) Median (months) Eribulin Dacarb Point of No Difference AJCC, American Joint Committee on Cancer. Schöffski P et al. Lancet. 2016;387: Favors eribulin Favors dacarbazine
43 Eribulin improves Progression-free survival in Liposarcoma Patients vs. dacarbazine PFS significantly better with eribulin compared with dacarzabine (2.9 vs 1.7; HR: [95% CI: ]; nominal p = ). Demetri GD et al. J Clin Oncol Oct 20;35(30):
44 Eribulin improves Overall survival in Liposarcoma Patients vs. dacarbazine OS was longer with eribulin treatment compared with dacarbazine (15.6 vs 8.4 months; HR: 0.511; 95% CI: ; nominal p = ). OS MEDIAN 15.6 vs. 8.4 months Demetri GD et al. J Clin Oncol Oct 20;35(30):
45 Eribulin: Histology-specific FDA approval January 2016 Eribulin is FDA approved only for liposarcomas after prior doxorubicin-based chemotherapy
46 What is the role for advanced molecular diagnostics with Next Generation Sequencing (NGS) Tests in choosing therapy for advanced Soft Tissue Sarcomas?
47 GIST Undifferentiated Sarcoma
48 Strong TRK expression by IHC
49 Large Gene Panel NGS Analysis of Undifferentiated Sarcoma (not GIST) Patient
50 Impact of TRK-inhibitor (Larotrectenib) on Patient with Undifferentiated Sarcoma (not GIST) with NTRK1-fusion Confirmed major Partial Remission after 2 cycles of larotrectinib Baseline Cycle 4
51 Progression on Larotrectenib after 7 months in Metastatic Undifferentiated Sarcoma , LOXO-EXT-17007, Dana Farber New Baseline End of cycle 1 of 2 nd Generation TRK inhibitor
52 Disappointing Level of Activity of Immune Checkpoint Inhibitors in Sarcoma Patients Objective Responses 4/10 Undiff Pleomorphic Sarcomas 2/9 Liposarcomas (de-diff)
53 Disappointing Level of Activity of Immune Checkpoint Inhibitors in Sarcoma Patients Nivolumab Alone Nivolumab + Ipilimumab
54 Disappointing Level of Activity of Immune Checkpoint Inhibitors in Sarcoma Patients Nivolumab Alone PFS OS Nivolumab + Ipilimumab PFS OS
55 Efficacy of Autologous T-cells with Genetically Engineered to express an optimized T-Cell Receptor Targeting NY-ESO1: 60% Response Rate # ** ** * ** Modified from slide courtesy of Crystal McKall, Stanford
56 Other New Molecular Targeted Approaches for Therapy of Defined Subtypes of Soft Tissue Sarcomas
57 Epigenetic Next Generation Targets in Sarcomas Tazemetostat (EZH2 inhibitor) for INI-1 deficient malignant rhabdoid tumors and epithelioid sarcomas Tazemetostat Gounder et al. ASCO
58 Summary: New Approaches to GIST and Sarcomas There are several recent therapeutic advances in practice and in clinical practice for patients with sarcomas The first monoclonal antibody used for sarcomas (Olaratumab) with doxorubicin may improve survival, but needs phase III data to confirm Several new drugs for TKI-resistant GIST are promising Sarcomas continue to prove that translational research can improve the outcomes of patients with well-defined and carefully studied subsets based great science and careful clinical investigation
Scientific Perspectives of Olaratumab Beyond the Approval Indication
Scientific Perspectives of Olaratumab Beyond the Approval Indication William D. Tap, MD Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center GEIS XVI International Symposium October
More informationGIST: imatinib and beyond
GIST: imatinib and beyond Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST) Michael Heinrich 1, Robin Jones 2, Margaret von Mehren 3, Patrick Schoffski 4, Sebastian Bauer 5,
More informationBLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations
BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations Erica Evans Ph.D. New Drugs on the Horizon 2017 AACR Annual Meeting April 2, 2017 Disclosures
More informationOverview of New Drugs for GIST following resistance to standard TKIs (imatinib and sunitinib)
Overview of New Drugs for GIST following resistance to standard TKIs (imatinib and sunitinib) George D. Demetri, M.D. Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Harvard Medical School
More informationClinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST)
Clinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST) Michael Heinrich 1, Robin Jones 2, Margaret von Mehren 3, Patrick
More informationUpdate on new agents in Gastrointestinal Tumor (GIST)
Update on new agents in Gastrointestinal Tumor (GIST) Albiruni R Abdul Razak Medical Oncology Sarcoma Site Lead Princess Margaret Cancer Centre/Mount Sinai Hospital 21 st October 2017 1 Disclosure Research
More informationLong Term Results in GIST Treatment
Long Term Results in GIST Treatment Dr. Laurentia Gales Prof. Dr. Rodica Anghel, Dr. Xenia Bacinschi Institute of Oncology Prof Dr Al Trestioreanu Bucharest 25 th RSRMO October 15-17 Sibiu Background Gastrointestinal
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationAvapritinib is Highly Active and Well-tolerated in Patients With Advanced GIST Driven by a Diverse Variety of Oncogenic Mutations in KIT and PDGFRA
Avapritinib is Highly Active and Well-tolerated in Patients With Advanced GIST Driven by a Diverse Variety of Oncogenic Mutations in KIT and PDGFRA Michael Heinrich, Margaret von Mehren, Robin L. Jones,
More informationIan Judson and Winette T. van der Graaf
SARCOMA Olaratumab really a breakthrough for soft-tissue sarcomas? Ian Judson and Winette T. van der Graaf In a recent study, the addition of olaratumab to doxorubicin chemotherapy for patients with soft-tissue
More informationLatest Advances in Targeted Therapy and Immunotherapy in Sarcomas. Robin L Jones Royal Marsden Hospital Institute of Cancer Research
Latest Advances in Targeted Therapy and Immunotherapy in Sarcomas Robin L Jones Royal Marsden Hospital Institute of Cancer Research Disclosures Consultant for: Adaptimmune Blueprint Clinigen Eisai Epizyme
More informationDCC-2618, a novel pan-kit and PDGFR
DCC-2618, a novel pan-kit and PDGFRα Kinase switch control inhibitor demonstrates encouraging activity in patients (pts) with Gastrointestinal Stromal Tumors (GIST) N. Somaiah, A. Razak, M. Gordon, F.
More informationEncouraging activity of novel pan-kit and PDGFRα inhibitor DCC-2618 in patients (pts) with gastrointestinal stromal tumor (GIST)
2017 ESMO Proffered Paper Encouraging activity of novel pan-kit and PDGFRα inhibitor DCC-2618 in patients (pts) with gastrointestinal stromal tumor (GIST) F Janku, A Razak, M Gordon, D Flynn, M Kaufman,
More informationManaging adult soft tissue sarcomas and gastrointestinal stromal tumours
Managing adult soft tissue sarcomas and gastrointestinal stromal tumours Sarcomas and gastrointestinal stromal tumours include a wide variety of biologically diverse cancers, many of them very rare. Paolo
More informationSarcoma. Suzanne George, MD Dana-Farber/Brigham and Women s Cancer Center. Chandrajit P. Raut, MD, MSc Dana-Farber/Brigham and Women s Cancer Center
Sarcoma Suzanne George, MD Dana-Farber/Brigham and Women s Cancer Center Chandrajit P. Raut, MD, MSc Dana-Farber/Brigham and Women s Cancer Center July 21, 2016 Moderated by Shannon K. Ryan Conferences
More informationArticle: Young, R.J. and Woll, P.J. (2016) Eribulin in soft-tissue sarcoma. Lancet, 387 (10028). pp ISSN
This is a repository copy of Eribulin in soft-tissue sarcoma.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/95897/ Version: Accepted Version Article: Young, R.J. and Woll,
More informationGastrointestinal stromal tumors (GIST)
Gastrointestinal stromal tumors (GIST) JY Blay Professor of Medicine GIST : standard of care Nosology : not a single disease Treatment of localized GIST Adjuvant treatment Treatment of advanced GIST First
More informationClinical Trials. Phase II Studies. Connective Tissue Oncology Society. Jon Trent, MD, PhD
Clinical Trials Phase II Studies Jon Trent, MD, PhD Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center Connective Tissue Oncology Society GIST Overview
More informationJon Trent, MD, PhD. Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center
Gastrointestinal Stromal Tumor GISTS 2010: After Standard of Care Jon Trent, MD, PhD Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center jtrent@mdanderson.org
More informationTargeting Sarcomas The Advancement of Molecularly Driven Therapies
Targeting Sarcomas The Advancement of Molecularly Driven Therapies Victor M. Villalobos, M.D., Ph.D. Assistant Professor Director, Sarcoma Medical Oncology Director, T3 (Target-based Therapeutics Team)
More informationThe Clinical Approach to Wild Type GIST. Margaret von Mehren, MD Professor and Director of Sarcoma Oncology Fox Chase Cancer Center
The Clinical Approach to Wild Type GIST Margaret von Mehren, MD Professor and Director of Sarcoma Oncology Fox Chase Cancer Center Disclosure slide Scientific Advisor to Novartis, Pfizer, Merck Research
More informationThe hunting of the sarcoma
The hunting of the sarcoma Update of Recent Advances in Soft Tissue Sarcoma Treatment Lin Mei, MD Hematology-Oncology Fellow Educational goal Anecdote of sarcoma (10 quiz) Review of pathology Neoadjuvant
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationTherapeutic Algorithms in systemic sarcoma therapy
Therapeutic Algorithms in systemic sarcoma therapy Ian Judson Sarcoma Unit Royal Marsden Hospital What evidence do we have? What sorts of evidence are there? Experience personal, peers ( Bayesian ) Educational
More informationTrabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract
Results of a Prospective Randomized Phase III T-SAR Trial Comparing Trabectedin vs Best Supportive Care (BSC) in Patients With Pretreated Advanced Soft Tissue Sarcoma (ASTS) Abstract 11508 Le Cesne A,
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Update on high dose imatinib for gastrointestinal stromal tumour (GIST) harbouring KIT exon 9 mutations
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Update on high dose imatinib for gastrointestinal stromal tumour (GIST) harbouring KIT exon 9 mutations Summary Date prepared: May 2012 Imatinib was the first
More informationINITIAL RESULTS OF PHASE 1 STUDY OF DCC-2618, A BROAD-SPECTRUM KIT AND PDGFR
INITIAL RESULTS OF PHASE 1 STUDY OF DCC-2618, A BROAD-SPECTRUM KIT AND PDGFR INHIBITOR, IN PATIENTS (PTS) WITH GASTROINTESTINAL STROMAL TUMOR (GIST) BY NUMBER OF PRIOR REGIMENS. S George, M Heinrich, P
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationTherapeutic strategies for wild-type gastrointestinal stromal tumor: is it different from KIT or PDGFRA-mutated GISTs?
Editorial Therapeutic strategies for wild-type gastrointestinal stromal tumor: is it different from KIT or PDGFRA-mutated GISTs? Toshirou Nishida Department of Surgery, National Cancer Center Hospital,
More informationOriginal Article. Keywords: Gastrointestinal stromal tumors (GIST); KIT; tyrosine kinase inhibitors (TKIs); immunohistochemical staining
Original Article Treatment of non-resectable and metastatic gastrointestinal stromal tumors: experience with the use of tyrosine kinase inhibitors in a third level hospital in Mexico Abdel Karim Dip Borunda,
More informationHistotype or molecular driven treatment of sarcomas?
Histotype or molecular driven treatment of sarcomas? Prof.ssa Maria A Pantaleo Dipartimento Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna GistStudyGroup Sarcomastudygroup Bologna
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationJY Blay. New horizons 2011
Prevention of GIST resistance JY Blay Medical Oncology Chairman of the Soft Tissue and Bone Sarcoma Group of EORTC Chairman of the CONTICANET Network of Excellence 6th Framework Program of the European
More informationSarcomas. Living Beyond Cancer A-Z UT Health San Antonio MD Anderson Cancer Center
Sarcomas Living Beyond Cancer A-Z UT Health San Antonio MD Anderson Cancer Center Aaron Sugalski, DO Associate Professor of Pediatric Hematology/Oncology Medical Director, UHS Pediatric Blood and Cancer
More informationAddressing Key Mechanisms of Tumor Drug Resistance
Addressing Key Mechanisms of Tumor Drug Resistance April 2018 Kinase switch control inhibitors for tumortargeted and immune-targeted cancer therapies Disclaimer This presentation has been prepared by Deciphera
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationKeep Calm and Love France. Robin L Jones Royal Marsden Hospital Institute of Cancer Research
Keep Calm and Love France Robin L Jones Royal Marsden Hospital Institute of Cancer Research Plan Parallels between France - UK - USA Importance of centralized care Improving Outcome Guidance (IOG) in UK/
More informationReference No: Author(s) NICaN Drugs and Therapeutics Committee. Approval date: 12/05/16. January Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Gastro- Intestinal Stromal Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationKey Words. Imatinib Gleevec KIT CD117 Gastrointestinal stromal tumors
The Oncologist Regulatory Issues: FDA The Oncologist CME Program is located online at http://cme.theoncologist.com/. To take the CME activity related to this article, you must be a registered user. Approval
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationREGORAFENIB IN METASTATIC COLORECTAL CANCER AND ADVANCED SOFT TISSUE SARCOMAS
REGORAFENIB IN METASTATIC COLORECTAL CANCER AND ADVANCED SOFT TISSUE SARCOMAS Summary of Presentations from the 2016 Meeting of The American Society of Clinical Oncology (ASCO) held in Chicago, Illinois,
More informationMesenchymal neoplasms of the gastrointestinal tract what s new? Newton ACS Wong Department of Histopathology Bristol Royal Infirmary
Mesenchymal neoplasms of the gastrointestinal tract what s new? Newton ACS Wong Department of Histopathology Bristol Royal Infirmary Talk plan Summary from 2010 talk. What s happened since 2010. GISTs
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationGIST PDX Models. Discover the world s most comprehensive GIST PDX collection, fully characterized for KIT mutations
GIST PDX Models Discover the world s most comprehensive GIST PDX collection, fully characterized for KIT mutations Accelerate your GIST targeted agent drug discovery programs with CrownBio s panel of well
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationImmunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center
Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated
More informationBest of ASCO 2014 Sarcoma
Best of ASCO 2014 Sarcoma Robin L Jones Seattle Cancer Care Alliance University of Washington Fred Hutchinson Cancer Research Center Presentation Outline Overview progress made in sarcoma Highlight 2 trials
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationI sarcomi dei tessuti molli
Novità e sequenze terapeutiche nelle neoplasie ginecologiche, melanoma e tumori rari: I sarcomi dei tessuti molli Giacomo G. Baldi Oncologia Medica Sandro Pitigliani Nuovo Ospedale S.Stefano Azienda USL
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Adjuvant imatinib after complete resection of primary gastrointestinal stromal tumour (GIST) in patients at high risk of relapse May 2012 Summary NICE guidance
More informationNational Horizon Scanning Centre. Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours. August 2008
Imatinib (Glivec) for adjuvant therapy in gastrointestinal stromal tumours August 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationCheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer
CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,
More informationAdvanced and metastatic soft tissue sarcoma, a review of aajcc 8th edition staging and the use of olaratumab.
Review article http://www.alliedacademies.org/journal-cancer-immunology-therapy/ Advanced and metastatic soft tissue sarcoma, a review of aajcc 8th edition staging and the use of olaratumab. Hari A Deshpande
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationIMATINIB MESYLATE THERAPY IN ADVANCED GASTROINTESTINAL STROMAL TUMORS: EXPERIENCE FROM A SINGLE INSTITUTE
IMATINIB MESYLATE THERAPY IN ADVANCED GASTRINTESTINAL STRMAL TUMRS: EXPERIENCE FRM A SINGLE INSTITUTE Hui-Hua Hsiao, 1,2 Yi-Chang Liu, 2 Hui-Jen Tsai, 2 Li-Tzong Chen, 1,2 Ching-Ping Lee, 2 Chieh-Han Chuan,
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
GIST (Gastrointestinal stromal tumor) Updated MARCH 2017 by Dr. Doreen Ezeife, PGY-5 Resident, University of Calgary Reviewed by Dr. Jan-Willem Henning (Staff Medical Oncologist, University of Calgary)
More informationSummary... 2 SARCOMA Neoadjuvant chemotherapy in patients with localised high-risk STS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 SARCOMA... 3 Neoadjuvant chemotherapy in patients with localised high-risk STS... 3 No additional benefit with evofosfamide
More informationLUNG CANCER IN FOCUS. ALK Inhibitors in Non Small Cell Lung Cancer: How Many Are Needed and How Should They Be Sequenced?
LUNG CANCER IN FOCUS Current Developments in the Management of Section Editor: Mark A. Socinski, MD ALK Inhibitors in Non Small Cell : How Many Are Needed and How Should They Be Sequenced? Alice T. Shaw,
More informationA stratified clinical approach to uterine sarcoma
A stratified clinical approach to uterine sarcoma Martee L. Hensley, MD Memorial Sloan-Kettering Cancer Center Gynecologic Medical Oncology Weill Cornell Medical College New York, NY USA Disclosure slide
More informationOptimizing Tyrosine Kinase Inhibitor Therapy in Gastrointestinal Stromal Tumors: Exploring the Benefits of Continuous Kinase Suppression
The Oncologist Gastrointestinal Cancer Optimizing Tyrosine Kinase Inhibitor Therapy in Gastrointestinal Stromal Tumors: Exploring the Benefits of Continuous Kinase Suppression AXEL LE CESNE, a JEAN-YVES
More informationEarly Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationRare Cancers. Andrew J. Wagner, MD, PhD Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Sarcoma Patient Symposium October 15, 2017
Rare Cancers Andrew J. Wagner, MD, PhD Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Sarcoma Patient Symposium October 15, 2017 Why should we care about Rare Cancers? Raise your hand
More informationSupplementary Online Content
Supplementary Online Content Joensuu H, Wardelmann E, Sihto H, et al. Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib: an
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationPerspectives in 2 nd line treatment of advanced Soft tissue Sarcoma treatment approaches. Dr.Dana Stănculeanu Bucharest Institute of Oncology
Perspectives in 2 nd line treatment of advanced Soft tissue Sarcoma treatment approaches Dr.Dana Stănculeanu Bucharest Institute of Oncology Epidemiology of soft tissue sarcoma STS accounts for
More informationEvan J. Lipson, M.D.
Update on treatment for Merkel cell, cutaneous squamous cell and basal cell cancers Evan J. Lipson, M.D. The Johns Hopkins University School of Medicine Bloomberg~Kimmel Institute for Cancer Immunotherapy
More informationWill All Adjuvant Therapy Trials Be Negative in RCC?
Will All Adjuvant Therapy Trials Be Negative in RCC? Tim Eisen Eleventh European International Kidney Cancer Symposium 29-30 April 2016 Crowne Plaza Barcelona Fira Center, Barcelona, Spain Tim Eisen -
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationAn update on systemic treatment of differentiated and medullary thyroid cancers: What to do after RAI
An update on systemic treatment of differentiated and medullary thyroid cancers: What to do after AI Disclosures: clinical trial support: - Exelixis, BI, Bayer, ECOG, TOG, GSK - Actogenix, Proacta, BMS,
More informationKIT Inhibition in Advanced Melanoma: Rationale and Clinical i l Results
KIT Inhibition in Advanced Melanoma: Rationale and Clinical i l Results Richard D. Carvajal, M.D. Assistant Attending Physician Melanoma/Sarcoma Service Memorial Sloan-Kettering Cancer Center Disclosures
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationAnalysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors
Ann Surg Oncol DOI 10.1245/s10434-014-3632-7 ORIGINAL ARTICLE BONE AND SOFT TISSUE SARCOMAS Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationRecent Advances in Lung Cancer: Updates from ASCO Updates from ESMO, AACR and ASCO
Recent Advances in Lung Cancer: Updates from ASCO 2018 Updates from ESMO, AACR and ASCO Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University
More informationColon cancer: Highlights. Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano
Colon cancer: Highlights Filippo Pietrantonio Istituto Nazionale dei Tumori di Milano Agenda 1) Metastatic colorectal cancer First-line treatment molecularly unselected: FOLFOXIRI-bev (CHARTA trial) Later-line
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationResponse to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation
DOI 10.1186/s13569-015-0036-9 CLINICAL SARCOMA RESEARCH CASE REPORT Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation Andrew S. Brohl 1*, Elizabeth G. Demicco
More information